CN103908436B - 一种速释型恩替卡韦组合物 - Google Patents
一种速释型恩替卡韦组合物 Download PDFInfo
- Publication number
- CN103908436B CN103908436B CN201210598062.8A CN201210598062A CN103908436B CN 103908436 B CN103908436 B CN 103908436B CN 201210598062 A CN201210598062 A CN 201210598062A CN 103908436 B CN103908436 B CN 103908436B
- Authority
- CN
- China
- Prior art keywords
- entecavir
- weight
- compositions
- surface stabilizer
- insoluble support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000980 entecavir Drugs 0.000 title claims abstract description 54
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 title claims abstract description 54
- 239000002131 composite material Substances 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 7
- 239000003381 stabilizer Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- 230000005660 hydrophilic surface Effects 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- -1 hydroxypropyl Chemical group 0.000 claims description 6
- 229920000578 graft copolymer Polymers 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 238000002242 deionisation method Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210598062.8A CN103908436B (zh) | 2012-12-29 | 2012-12-29 | 一种速释型恩替卡韦组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210598062.8A CN103908436B (zh) | 2012-12-29 | 2012-12-29 | 一种速释型恩替卡韦组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103908436A CN103908436A (zh) | 2014-07-09 |
CN103908436B true CN103908436B (zh) | 2016-02-10 |
Family
ID=51034643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210598062.8A Active CN103908436B (zh) | 2012-12-29 | 2012-12-29 | 一种速释型恩替卡韦组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103908436B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101028273A (zh) * | 2007-02-02 | 2007-09-05 | 广东东阳光药业有限公司 | 一种改进的恩替卡韦混悬颗粒及其制备方法 |
CN102106856A (zh) * | 2010-06-29 | 2011-06-29 | 江苏正大天晴药业股份有限公司 | 恩替卡韦药物组合物及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL150447A0 (en) * | 2000-02-29 | 2002-12-01 | Bristol Myers Squibb Co | Pharmaceutical compositions containing entecavir |
WO2011076412A1 (de) * | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Orale darreichungsform umfassend entecavir |
-
2012
- 2012-12-29 CN CN201210598062.8A patent/CN103908436B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101028273A (zh) * | 2007-02-02 | 2007-09-05 | 广东东阳光药业有限公司 | 一种改进的恩替卡韦混悬颗粒及其制备方法 |
CN102106856A (zh) * | 2010-06-29 | 2011-06-29 | 江苏正大天晴药业股份有限公司 | 恩替卡韦药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103908436A (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2005945B1 (en) | Oseltamivir phosphate granule and preparation method thereof | |
US20050196346A1 (en) | Powder inhaler formulations | |
US6558704B1 (en) | Process for preparing pellets containing up to 90 wt.% of a pharmaceutical active ingredient | |
MX2015002583A (es) | Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influencia de etanol. | |
JP2014516080A5 (zh) | ||
US9585845B2 (en) | Oral pharmaceutical composition comprising oseltamivir and method of preparing the same | |
CN104887633B (zh) | 一种利伐沙班片剂及其制备方法 | |
CN103372014B (zh) | 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法 | |
CN103520169B (zh) | 米氮平片及其制备方法 | |
JP2017122056A (ja) | 医薬含有造粒物の製造方法 | |
CN112933061B (zh) | 一种盐酸阿比多尔胶囊及其制备方法 | |
CN103908436B (zh) | 一种速释型恩替卡韦组合物 | |
RU2616500C2 (ru) | Композиция пазопаниба | |
CN112206225A (zh) | 君臣佐使配伍的抗新冠病毒西药生产方法 | |
CN110974787A (zh) | 泊沙康唑干混悬剂及其制备方法 | |
CN107412198A (zh) | 盐酸度洛西汀肠溶缓释颗粒剂及其制备方法 | |
CN103405387B (zh) | 一种新的头孢克肟干混悬剂及其制备方法 | |
CN112717137B (zh) | 含有磷酸奥司他韦的药物组合物及其制备方法 | |
CN103845323B (zh) | 麦考酚酸及其盐肠溶制剂和制备方法 | |
CN109833299B (zh) | 一种微粉化罗沙替丁醋酸酯药用盐微丸及其制备方法和其应用 | |
CN109833306B (zh) | 一种罗沙替丁醋酸酯药用盐缓释微丸及其制备方法和其应用 | |
CN107157943A (zh) | 一种托匹司他制剂及其制备方法 | |
ES2444591T3 (es) | Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada | |
CN104887625B (zh) | 含盐酸依福地平的混悬液及其固体制剂和制备方法 | |
CN109833308B (zh) | 一种罗沙替丁醋酸酯药用盐的载药微丸及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Quick-release type entecavir composition Effective date of registration: 20170321 Granted publication date: 20160210 Pledgee: Bank of Dongguan Limited by Share Ltd Hefei branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2017340000039 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180905 Granted publication date: 20160210 Pledgee: Bank of Dongguan Limited by Share Ltd Hefei branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2017340000039 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Quick-release type entecavir composition Effective date of registration: 20190328 Granted publication date: 20160210 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2019340000162 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200722 Granted publication date: 20160210 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: 2019340000162 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A quick release entecavir composition Effective date of registration: 20210322 Granted publication date: 20160210 Pledgee: China Construction Bank Co.,Ltd. Hefei government culture new area sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2021340000006 |